Member Info for Hedgehog100

LOL, Thanks ChazC,

Nice to know that a Z-list troll is trolling this with such inane nonsense.

That tells us all we need to know!

IQAI and Trevor Brown troll Elartu has been trolling the IQAI board afresh with some nasty little lies.
I don't intend to descend into the gutter with him, but I will respond with a few home truths about FDBK. Let's make it a round ten.
(Albeit they're probably obvious to many FDBK shareholders here ... how many have I heard say 'it's just not worth me selling now ...'?) -

• Public question marks about the company's strategy.
• A pitiful 4% sales growth (at its interim stage) after years of trying.
• £738K. annualised pre-tax losses at the interim stage.
• Those losses will increase with the recruitment drive etc.
• Current cash likely to be below £1M., probably enough for about a year.
• Little potential short term excitement expected.
• No exciting growth story.
• Chart in an entrenched downtrend, and generally declining trading volumes.
• No recent director share buying, despite the depressed share price, and not being in a close period.
• By the end of 2019 FDBK will be in fundraising countdown mode, with one due within months by then.

Who would like to predict the price of FDBK's next fundraising?
Current s.p. 0.725p, market cap. £2.71M.

Don't be surprised if IQAI's sales in the current year are actually HIGHER than FDBK's.
As well as its losses and current market cap. (£1.44M. at 1.2p) being LOWER.
And as regards turnover growth rate ... IQAI will just blow FDBK away.

Companies in FDBK's state don't tend to get taken over (except from the administrator if they've gone bust).
It looks to me like a 'lifestyle business' for some of the insiders here, but for how long will they be able to attract enough mug investors to stump up fresh funds?

"It's quite amazing how often errors occur around TB."

Elartu (aka LR2 on ADVFN),

The one who must try harder to avoid inaccuracies is yourself, as you've been guilty of multiple inaccuracies in your IQAI trolling.

I flagged up (on the ADVFN FDBK thread) one example a while ago, and two days ago I quoted another from you on the ADVFN IQAI thread.

And the difference between your criticism of IQAI inaccuracies, and your own inaccuracies, is this: theirs are benign/debateable, whereas your own are clear cut and seriously misleading.
Which is perhaps why you have had (by your own admission) multiple posts deleted on LSE, and been given a final warning about your conduct here.

Judging by your insulting post on the LSE FDBK board last Saturday, you are very seriously embittered about your disastrous investment in FDBK, and wish to hit out wildly to try to 'spread out the pain'.
You need to take responsibility for your own investment decisions and losses, and stop blaming an innocent party if it doesn't work out.

As regards your view of investors not liking IQAI: well, you're such a great judge of investments aren't you!!
On the contrary, your knowledge of business and investment seems to be next to minimal.
You're a 'tech geek', and not for the first time a 'tech geek' had become blinded by a company's technology, but missed the business case.

Obviously IQAI will not want to conduct a placing at a depressed share price, and before the FDA approval, and it's absurd to suggest they've tried (it would be very clear if they had).
After the FDA approval, investors will be queuing up to invest into such a stunning AI play as this, with such terrific prospects and lowly market cap.

Don't be surprised if IQAI's sales in the current year are actually HIGHER than FDBK's.
As well as its losses and current market cap. being lower (£1.44M. at 1.2p IQAI, £2.71M. at 0.725p FDBK).
And as regards turnover growth rate ... IQAI will just blow FDBK away.

Last August David Smith did a series of investor lunches, introducing himself, explaining the company products and future pipeline and laying out his vision for the company.

Here are a few points from one of those presentations:
• His deal is largely equity based, so he is aligned with us.*
• Whilst StoneChecker has great potential, the real winner could be the brain scanning software of IB, which should be extended to other areas. Liver was mentioned as achievable with minor tweaks.
• His plan is to deliver revenues of $20M. to $30M. annual within the next few years on existing products but double that with ‘planned’ products.
• He mentioned the possible need to land grab in order to build the business quickly at which point they would probably be taken out by GE or Phillips who provide the hardware but have poor software that is 20 years old in many cases.

The thing that really stands out is $10s of millions of annual revenue within the next few years.

This is a measure of the company's ambitions, and in view of David Smith's track record they have to be taken seriously.

If they manage to achieve this degree of success, then the company's market cap. will dwarf today's level (currently £1.56M. at 1.3p).

(* On 1 November 2018, 6,017,500 shares in IQ-AI Limited were granted under option to David Smith.
The shares are exercisable at 2.60p and the option will vest over 3 years, with 1/3(rd) vesting on 1 August 2019 and the remainder vesting at a rate of 1/36(th) per month on the last day of each month, until the shares become fully vested. The option will be exercisable for 10 years and will on 1 August 2028. There are no cash settlement alternatives.)

The listing and structure of IQAI (ex Flying Brands) is set up to be a much large company.

I.e. its main market listing, as opposed to AIM.

And the appointment of David Smith to an 'umbrella role' over StoneChecker Software and Imaging Biometrics, both of which also have their own CEOs (i.e. Nick Stevens and Michael Schmainda respectively). -

06-Aug-18 07:00 RNS Appointment of CEO to the Operating Subsidiaries Company Announcement - General
"Flying Brands Limited (the "Company" or "Flying Brands") is pleased to announce the appointment of Mr. David W.J. Smith as Chief Operating Officer and CEO of the group's two operating businesses, StoneChecker Software and Imaging Biometrics, with immediate effect
David has a 30-year history of successfully building life sciences businesses in Europe and the United States, including Biocompatibles plc where he initiated the ophthalmology and cardiology businesses in a period that saw their sales grow from zero to over GBP40m pa, business development for Carl Zeiss in which he reinvigorated their mature ophthalmology capital equipment business to grow more than 15% pa resulting in sales in excess of GBP150m. In addition, the foundation of California based Tenaxis Medical, where having raised $22m from investors David led the company through product development, built a strong operating team, achieved regulatory approvals and secured the company's first sales. Tenaxis Medical was sold for $178m in 2014.
Trevor Brown, CEO of Flying Brands, commented: "I am delighted to welcome David to Flying Brands. I believe that the Company will benefit greatly from the breadth of his experience, not only from his proven ability to actualize strategic vision into strongly growing revenue, but also from applying his deep knowledge of the US medical market to our growing Artificial Intelligence product portfolio."
The Directors of the Company accept responsibility for the contents of this announcement."
http://www.lse.co.uk/share-regulatory-news.asp?shareprice=FBDU&ArticleCode=jrprb8z4&ArticleHeadline=Appointment_of_CEO_to_the_Operating_Subsidiaries

David Smith's track record does nothing but inspire confidence.
He sold his last company for $178M., and before that played a leading role in driving sales at Biocompatibles from 0 to over £40M.
(Biocompatibles was acquired by BTG in 2010 for £177M.

How has someone of his magnitude been attracted to a micro cap like IQAI?
(Current market cap. £1.56M., at 1.3p.)

Certainly not because he expects it to stay at this size for long.

Like a coiled spring, and assisted by multiple resellers, active selling into the world's largest healthcare market (i.e. the multi trillion dollar US healthcare market) should make for a very exciting stream of positive sales newsflow.

It's the right product and the right time, so there's every reason to believe that sales will accelerate rapidly.

Note that IQAI now actually names specific resellers, in its 30.4.19 RNS: i.e.:
" ... This work is already underway with a series of resellers such as aycan Medical Systems, QMENTA, Blackford and Medimsight. ..."

It's fairly unusual to name companies before deals are actually announced, and in my opinion the fact that IQAI does so supports the view that these companies are keen to work with IQAI, and that deals could be announced shortly.

IQAI's 30.4.19 RNS also uses the term "marketing clearance" in respect of "FDA approval".
This suggests that they're ready and waiting to start the marketing process immediately.

Ob1trader,

I totally agree.

The words "final stages" and "shortly" suggest that we are now very close to FDA approval.
My sense is that it could now be imminent - perhaps even next week.

But the important thing is that we've in effect had confirmation that it will be approved, and that there has been no major hitch.

Approval should come as a major relief for all shareholders, and the share price should react accordingly.
The s.p. only fell much below 2p because of the approval delay, so that should be the minimum to be expected after clearance.

The fact that FDA approval has taken so long shows how rigorous the process is, and also what a great achievement it will be.
And one that will be monumental for IQAI's development, because America is such a vast and well-funded healthcare market, which is at the forefront of applying new technology.

And IQAI appears to have a range of potential US reseller agreements lined up, which could be ready for signing once FDA marketing approval is received.

This bodes well for a period of very positive IQAI newsflow in the near future, driving the share price to much higher levels ahead of the next fundraising.

SD, Shame on YOU, wasting the time of the company, and potentially the HMRC, with this silly nonsense about a negligible value claim. That is what is contemptible. The company has made great progress over the last few years, doubling GOS's turnover, controlling costs, and now looking to expand more into the private sector and RTO. Moreover, they have been very accommodating in chatting to investors on the phone, and welcoming their input. But they are not your unpaid IFA. Would you please stop wasting their time, and polluting these boards, with your silly nonsense, as you are sounding like a whingeing little child.

Thanks to Comedy for this post about Oyster on an ADVFN PLMO thread: comedy 27 Aug '17 - 09:38 - 507 of 512 3 0 "Well was in Oman...and djibouti is suroounded by oil...with American base now renewed lease for 20 years...ideal for American oil co.to start heading here...oyster have a head start...oyster could be worth 10times it value...question is when is plmo show getting on road???" https://uk.advfn.com/cmn/fbb/thread.php3?id=41208554&from=490

"A Major East Africa Explorer Developing World Class, Conventional Low Cost Oil & Gas Basins Oyster Oil and Gas Ltd - Corporate Finance Presentation | Q3 2017" Page 3: "EXECUTIVE SUMMARY Corporate Overview Listed on TSX Venture Exchange (Ticker “OY ”), Market Cap ~$20 million (at C$0.50/ share) E&P Objectives Developing major new oil/gas basins, focused on significant, low cost, conventional, (not landlocked) resource plays PSC’s are located in politically stable countries, with attractive full cycle economic terms Investor Objectives Shareholder Return: Developing major exploration prospects, farm-outs and drilling success Executive Team Highly experienced with successful industry track record in Africa & Middle East East Africa Portfolio Oyster holds rights to over 6 Million Acres with several highly prospective basins in located in East Africa: Djibouti Overview Oyster 100% WI in 4 Blocks: - 3 Onshore & 1 Offshore; ~3.5 million gross acres High Potential Frontier Exploration, with favourable PSC terms Large onshore basin confirmed, mature oil source present,and good quality reservoir potential Madagascar Overview Block 1101: Oyster holds 100% and Operatorship Block 1101 - 2.8 Million Acres; ~10 Billion* Barrels of oil mapped in a number of basins/prospects Active exploration program & major drilling event scheduled in next 30 months Business Development Strategy Oyster has a clear strategy to develop and monitise Portfolio Seeking an AIM IPO in Q2/Q3 2017 Note: * Figures based on company calculated STOIIP un-risked ** Company calculated P50 Mean recoverable resource (un-risked)" HTTP://www.oysteroil.com/s/presentations.asp

As I write, OY is still up 11.1% to 60 cents today in Canada (the Toronto exchange is still open). That's a new three-year high, and the highest since the oil price crash in 2014. And it certainly doesn't suggest that there's a problem with its AIM listing - on the contrary. Note that OY's latest presentation states: "Seeking an AIM IPO in Q2/Q3 2017"

Oyster is floating "in the near future", and started the process at least two months ago: "June 20, 2017 Oyster Announces an Update to CAD$1.5m Private Placement Financing, the Closing of Debt Settlement Agreement and also the intention to list on the AIM Market of the London Stock Exchange (the AIM Listing) … The Company is also pleased to announce that it intends to list its Common Shares on the AIM Market of the London Stock Exchange. The Company is in the process of engaging a nominated advisor and one or more brokers as well as other advisors in connection with the AIM Listing and will provide a further corporate update in due course. …" HTTP://www.oysteroil.com/s/news.asp?ReportID=793278&_Type=News&_Title=Oyster-Announces-an-Update-to-CAD1.5m-Private-Placement-Financing-the-Closi... "August 01, 2017 Oyster Announces Engagement of Advisers for Proposed AIM Listing and Closing of Second Tranche of Private Placement Vancouver, British Columbia -- August 1, 2017 -- Oyster Oil and Gas Ltd. ("Oyster" or the "Company") (OY: TSXV, 13L: FSE) is pleased to announce that in connection with the Company's proposed admission of its common shares to trading on AIM, a market of the London Stock Exchange (the "AIM Listing"), the Company has appointed Beaumont Cornish Limited as financial and nominated adviser and Peterhouse Corporate Finance Limited as broker. The Company anticipates the AIM Listing to occur in the near future. ..." HTTP://www.oysteroil.com/s/news.asp?ReportID=798969&_Type=News&_Title=Oyster-Announces-Engagement-of-Advisers-for-Proposed-AIM-Listing-and-Closin... Yahya, Your 'voices in your head' are talking nonsense, because Oyster isn't preparing to start legal proceedings, it's preparing to dual-list. A lot of the work will have been done already, and Oyster is such a quality company that it won't take long. A September listing looks very plausible to me. But in any case, OY & PLMO may start moving up well beforehand in anticipation (and indeed OY is moving up already), and both may also move up for other reasons. Both companies look great value, with a lot that could go on - including behind the scenes.

"I am going to try find solid time lines...one is bacanora but i am on the loo and will post timeframes of the lse admission as and when i find it." Yahya, Please don't bother. You've already ramped two of your stock picks here, and we're not interested in a third. This is the PLMO board: please save your ramping of other stocks for their own boards, or you may be reported to LSE, and possibly banned, as they are very strict.

"But nothing is expected to happen here until January." Yahya, Speak for yourself, mate! Oyster should list imminently, and PLMO's interim results next month could provide a positive update on the company's development, if indeed there is nothing earlier. If you look at PLMO's chart, you will see that it more than doubled in August-September last year, to over 0.08p. Something similar could happen this time round.

"Brexit pain for holidaymakers as pound expected to fall further against euro Investment bank Morgan Stanley predicts pound-euro parity by early next year Friday 11 August 2017 16.18 BST British holidaymakers should brace themselves for more Brexit pain when they change their pounds into euros, with a leading investment bank forecasting the currencies are on the way to parity. Sterling is trading at €1.09 after collapsing from €1.31 on the day before the UK voted to quit the European Union in June 2016. … Morgan Stanley believes the dilapidated British currency has further to fall, and is pencilling in pound-euro parity in the first three months of next year, when £1.02 will buy just €1. … Piling on the misery, the bank described Britain’s economic prospects as “bleak” as it heads for what appears to be a calamitous exit from the EU, with Tory ministers unable to provide clarity on their vision for life outside the bloc. Theresa May, Philip Hammond, Boris Johnson, Chris Grayling, Liam Fox and Michael Gove have given contradictory statements about Conservative plans for trade, customs, tariffs, immigration, air control, a transition period and countless other facets of Britain’s divorce. “The UK economic outlook looks bleak, with stretched household balance sheets, Brexit negotiation uncertainty potentially weighing on business investment, and net exports growth staying subdued despite a weak pound,” Morgan Stanley analysts said. “On the politics front, risks have also increased, with the Conservative party showing split opinions on the UK’s Brexit position, revealing inner party tensions.” In contrast, the eurozone is on the up, with its economy expanding twice as fast as the UK in recent months. ..." https://www.theguardian.com/business/2017/aug/11/brexit-pain-for-holidaymakers-as-pound-set-to-fall-further-against-euro

Morgan Stanley are predicting pound-euro parity by early 2018, which could dovetail closely with a ZMNO return of cash to shareholders, increasing the sterling value of ZMNO's euro cash significantly by that point. So the expected EUR5.3M. gross for distribution to shareholders &/or an acquisition would equate to £5.3M. (on the basis of £1 = EUR1 in early 2018). There should also be some interest accruing. Ongoing costs should be relatively minor once ZMNO's operating business is gone, so potentially the cash return could be over 5p per share. An acquisition could reduce the payout, but with the bonus of using the value of ZMNO's listings. E.g. perhaps about 4p per share returned to shareholders, with about a million quid or so retained to accompany a RTO. In conclusion, a good defensive share in case of a plunging sterling and stockmarket, but with good upside based on the expected cash payout, and still with the spice of a potential RTO. And remember that the annualised percentage profit from any cash return in 6 months is actually double.

"Pure cash Shell - 18% discount Tue 08:52 ... Cash after sale per RNS £4,732,000 (€5,300,000 less €100k for liquidation / return of cash)..." Rifteastafrica, Thanks for flagging up that there will still be some costs after the disposal, albeit probably relatively minor unless perhaps there is an acquisition: I should have made that clear in my post on Monday so apologies for that.

Although PLMO's track-record has been poor, a shell should never be written off until it's definitely over. Because there's always the potential for new management, new finance, and a new strategy ... to give a touch of the CHA CHA CHA. The renowned shell Concha (CHA) 40-bagged in 2014, to a market cap. of over £100M. at its peak. But CHA's initial investments in 2013 had quickly failed, and the share had to be refinanced. And there are some similarities to CHA's position then and PLMO's at the moment, at 0.022p. One of these is that PLMO's broker is Peterhouse Corporate Finance, who are also broker to CHA, and were CHA's joint broker in 2014 when the share 40-bagged. http://www.polemos.co.uk/aim-rule-26/advisors

Another correction! - I'm sure that Adam Reynolds is committed to eventually returning NEW to the market as a RTO!

ZMNO has risen 0.25p today, to 4.0p, market cap. £3.98M. In comparison, the expected EUR5.3M. for distribution to shareholders &/or an acquisition equates to £4.82M. (£1 = EUR1.1). RTO prospects are in for free, with a healthy leeway besides.